Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Tenofovir disoproxil fumarate (TDF) is commonly prescribed as a fixed-dose, co-formulated antiretroviral drug for HIV-1 infection. The major concern of long-term TDF use is renal dysfunction. However, little is known about the long-term patterns of changes in renal function in HIV-infected Koreans receiving TDF. Materials and Methods: We prospectively followed 50 HIV-infected Koreans, performing laboratory tests every 3 months during the first year and every 6 months for the next 2 years. Urine N-acetyl-β-D-glucosaminidase (NAG) and plasma cystatin-C were measuredusing samples collected in the first year. Data on renal function were retrospectively collected on HIV-infected patients receivingfirst-line TDF (n=40) and in antiretroviral therapy (ART)-naïve patients (n=24) for 3 years. Renal function was evaluated as estimated glomerular filtration rate (eGFR) from serum creatinine [Modification of Diet in Renal Disease (MDRD)] and cystatin-C. Results: The eGFR (cystatin-C) showed significant changes from 0 to 48 wks (p=0.002), with the lowest levels at 24 wks (84.3±18.8 mL/min vs. 90.3±22.5 mL/min, p=0.021 by post hoc test). Urine NAG levels did not differ at 0, 12, 24, and 48 wks, although eGFR (MDRD) significantly decreased from 0 (98.7±18.9 mL/min/1.73 m2) to 144 wks (89.0±14.7 mL/min/1.73 m2) (p=0.010). The first-line TDF group had significantly lower eGFR (MDRD) than the ART-naïve group at 144 wks (89.7 mL/min/1.73 m2 vs. 98.4 mL/min/1.73 m2, p=0.036). Thirteen (26%) participants experienced a decrease in renal impairment of 10 mL/min/1.73 m2 in eGFR (MDRD) at 144 wks. Conclusion: These data suggest that clinically meaningful renal injury can develop in HIV-infected Koreans receiving long-term TDF.
Abstract
Purpose: Tenofovir disoproxil fumarate (TDF) is commonly prescribed as a fixed-dose, co-formulated antiretroviral drug for HIV-1 infection. The major concern of long-term TDF use is renal dysfunction. However, little is known about the long-term patterns of changes in renal function in HIV-infected Koreans receiving TDF. Materials and Methods: We prospectively followed 50 HIV-infected Koreans, performing laboratory tests every 3 months during the first year and every 6 months for the next 2 years. Urine N-acetyl-β-D-glucosaminidase (NAG) and plasma cystatin-C were measuredusing samples collected in the first year. Data on renal function were retrospectively collected on HIV-infected patients receivingfirst-line TDF (n=40) and in antiretroviral therapy (ART)-naïve patients (n=24) for 3 years. Renal function was evaluated as estimated glomerular filtration rate (eGFR) from serum creatinine [Modification of Diet in Renal Disease (MDRD)] and cystatin-C. Results: The eGFR (cystatin-C) showed significant changes from 0 to 48 wks (p=0.002), with the lowest levels at 24 wks (84.3±18.8 mL/min vs. 90.3±22.5 mL/min, p=0.021 by post hoc test). Urine NAG levels did not differ at 0, 12, 24, and 48 wks, although eGFR (MDRD) significantly decreased from 0 (98.7±18.9 mL/min/1.73 m2) to 144 wks (89.0±14.7 mL/min/1.73 m2) (p=0.010). The first-line TDF group had significantly lower eGFR (MDRD) than the ART-naïve group at 144 wks (89.7 mL/min/1.73 m2 vs. 98.4 mL/min/1.73 m2, p=0.036). Thirteen (26%) participants experienced a decrease in renal impairment of 10 mL/min/1.73 m2 in eGFR (MDRD) at 144 wks. Conclusion: These data suggest that clinically meaningful renal injury can develop in HIV-infected Koreans receiving long-term TDF.
참고문헌 (42)
- Hemkens LG, "Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis", HIV Clin Trials, 16, pp.178~189 (2015)
- Prasitsuebsai W, "Treatment outcomes and resistance patterns of children and adolescents on second-line antiretroviral therapy in Asia", J Acquir Immune Defic Syndr, 72, pp.380~386 (2016)
- Brooks K, "Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya", J Int AIDS Soc, 19, pp.20798~ (2016)
- Labhardt ND, "Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?", Trop Med Int Health, 20, pp.914~918 (2015)
- Gallant JE, "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial", JAMA, 292, pp.191~201 (2004)
- Tourret J, "Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?", J Am Soc Nephrol, 24, pp.1519~1527 (2013)
- Casado JL, "Renal and bone toxicity with the use of tenofovir: understanding at the end", AIDS Rev, 18, pp.59~68 (2016)
- Del Palacio M, "Proximal tubular renal dysfunction or damage in HIV-infected patients", AIDS Rev, 14, pp.179~187 (2012)
- Hall AM, "Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence", Am J Kidney Dis, 57, pp.773~780 (2011)
- Kohler JJ, "Tenofovir renal toxicity targets mitochondria of renal proximal tubules", Lab Invest, 89, pp.513~519 (2009)
- Lebrecht D, "Mitochondrial tubulopathy in tenofovir disoproxil fumaratetreated rats", J Acquir Immune Defic Syndr, 51, pp.258~263 (2009)
- Ramamoorthy H, "Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate nephrotoxicity", J Biochem Mol Toxicol, 28, pp.246~255 (2014)
- Nishijima T, "Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study", Clin Infect Dis, 55, pp.1558~1567 (2012)
- Rodríguez-Nóvoa S, "Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study", Clin Infect Dis, 48, pp.e108~e116 (2009)
- Dauchy FA, "Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy", Kidney Int, 80, pp.302~309 (2011)
- Labarga P, "Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir", AIDS, 23, pp.689~696 (2009)
- Andrade-Fuentes K, "Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico", AIDS Patient Care STDS, 29, pp.181~185 (2015)
- Nishijima T, "Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients", PLoS One, 6, pp.e22661~ (2011)
- Nishijima T, "Renal function declines more in tenofovir- than abacavirbased antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection", PLoS One, 7, pp.e29977~ (2012)
- Nishijima T, "Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up", AIDS, 28, pp.1903~1910 (2014)
- Quesada PR, "Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients", Int J Clin Pharm, 37, pp.865~872 (2015)
- Rokx C, "How does weight influence tenofovir disoproxil-fumarate induced renal function decline?", AIDS, 29, pp.643~645 (2015)
- Onopiuk A, "Cystatin C: a kidney function biomarker", Adv Clin Chem, 68, pp.57~69 (2015)
- WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
- 오상우, "Obesity and Metabolic Syndrome in Korea", Diabetes and Metabolism Journal, 35(6), pp.561~566 (2011), 대한당뇨병학회
- Levey AS, "Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate", Ann Intern Med, 145, pp.247~254 (2006)
- Larsson A, "Calculation of glomerular filtration rate expressed in mL", min from plasma cystatin C values in mg, Scand J Clin Lab Invest, pp.2004, 64[DOI]
- Nishijima T, "Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study", J Infect Chemother, 19, pp.850~857 (2013)
- Roldán V, "Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding)", Am J Cardiol, 111, pp.1159~1164 (2013)
- Levey AS, "Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)", Kidney Int, 67, pp.2089~2100 (2005)
- Kyaw NT, "Low incidence of renal dysfunction among HIV-infected patients on a tenofovir-based first line antiretroviral treatment regimen in myanmar", PLoS One, 10, pp.e0135188~ (2015)
- Pujari SN, "Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom", BMC Infect Dis, 14, pp.173~ (2014)
- Chua AC, "Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort", AIDS Res Ther, 9, pp.19~ (2012)
- Mizushima D, "Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study", J Infect Chemother, 20, pp.784~788 (2014)
- Chaisiri K, "Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight", Curr HIV Res, 8, pp.504~509 (2010)
- Stevens LA, "Advances in glomerular filtration rate-estimating equations", Curr Opin Nephrol Hypertens, 19, pp.298~307 (2010)
- Chew-Harris JS, "The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men", Ann Clin Biochem, 50(Pt 1), pp.39~46 (2013)
- Stevens LA, "Factors other than glomerular filtration rate affect serum cystatin C levels", Kidney Int, 75, pp.652~660 (2009)
- Inker LA, "Estimating glomerular filtration rate from serum creatinine and cystatin C", N Engl J Med, 367, pp.20~29 (2012)
- Longenecker CT, "Reductions in plasma cystatin C after initiation of antiretroviral therapy are associated with reductions in inflammation: ACTG A5224s", J Acquir Immune Defic Syndr, 69, pp.168~177 (2015)
- Schley G, "Comparison of plasma and urine biomarker performance in acute kidney injury", PLoS One, 10, pp.e0145042~ (2015)
- Charlton JR, "A basic science view of acute kidney injury biomarkers", Nephrol Dial Transplant, 29, pp.1301~1311 (2014)